Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
|
31694905 |
2020 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, TBMS1 is a promising compound for the treatment of glioblastoma and an inhibitor of MET.
|
31349699 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies reveal a novel mechanism to alter the recycling process of MET in glioblastoma cancer cells by promoting the receptor degradation through a proteasome-sensitive and lysosome-dependent pathway through the ligand-independent activation of MET using anti-MET antibodies.
|
30760737 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that the level of miR-562 was downregulated in GBM tissues and the expression of c-MET was upregulated in tumors.
|
30613151 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the five target genes that were enriched in the glioblastoma pathway, in the WikiPathway database, both HRas proto-oncogene, GTPase and MET proto-oncogene, receptor tyrosine kinase target genes of hsa-miR-139-5p, were found to be significantly associated with patient survival.
|
31423264 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET and its ligand hepatocyte growth factor (HGF) play a critical role in the proliferation, survival, migration, invasion, angiogenesis, stem cell characteristics, and therapeutic resistance and recurrence of glioblastomas.
|
31221203 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intravenous administration of this formulation enhanced the curative efficacy of TMZ by downregulating the hepatocyte growth factor receptor (c-MET) gene in GBM U87 cells.
|
30982841 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified critical proteins that were altered in MET inhibitor-resistant GBM including mTOR, FGFR1, EGFR, STAT3, and COX-2.
|
30201763 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma.
|
29743557 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
H1/pHGFK1 exerts anti-tumoural and radiosensitive activities mainly through the inhibition and reversal of IR-induced MET and ATM-Chk2 axis activities in glioblastoma.
|
29348487 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
|
29238047 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors.
|
28751462 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas.
|
28668888 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
|
28504721 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the potential of integrated 11C-MET-PET/MRI for response assessment of GBM and the utility of combined assessment of morphologic and metabolic information with the proposal for assessing relapsed GBM.
|
28258444 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In both cohorts, MET amplification was never detected in GBM devoid of strongly immunopositive cells.
|
26946354 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study we investigated ALK, ROS1, and MET status in nine glioblastoma stem cell lines and tumors from which they arise.
|
28960893 |
2017 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This translational correlative component to the MET-PET clinical trials can lead to a better understanding of the existing controversies and can enhance our knowledge for future randomization of GBM patients based on their tumor gene signatures to achieve better prognosis and treatment outcome.
|
29164057 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recurrence of GB after chemo-radiation could be associated with a variation in PlGF and MET expression.
|
27566180 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
|
27748748 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we showed that PKCδ was aberrantly activated in GBM cells by c-MET, a receptor tyrosine kinase hyperactivated in GBM.
|
26700818 |
2016 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PV-O glioblastomas were associated with lower expression of VEGFC (p = 0.032) than other periventricular locations, whereas MET overexpression remained exceptional.
|
26637806 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeting MET and then inhibiting the downstream signaling.
|
26250785 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
|
26381735 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that the RTKs MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in GBM.
|
24440911 |
2014 |